Targeting DGAT1 represents a promising strategy to disrupt metabolic-stromal cross-talk and mitigate race-associated disparities in prostate cancer progression.<h4>Significance</h4>This study highlights DGAT1-driven lipid accumulation in CAFs from AA patients with prostate cancer as a key driver of fibroblast activation and tumor-promoting roles contributing to racial disparities. Here, DGAT1 is linked to prostate carcinoma.